Middle East & Africa pulmonary arterial hypertension Market is expected to reach US$ 535.74 Million by 2028

At 4.5% CAGR, the Middle East & Africa Pulmonary Arterial Hypertension Market is projected to be worth US$ 535.74 million by 2028, says The Insight Partners

According to The Insight Partners’ research, the Middle East & Africa pulmonary arterial hypertension market was valued at US$ 410.88 million in 2022 and is expected to reach US$ 535.74 million by 2028, registering a CAGR of 4.5% from 2022 to 2028. Rising clinical trials for drugs development to treat pulmonary arterial hypertension and availability of generics at affordable costs due to growing patent expiration are the critical factors attributed to the Middle East & Africa pulmonary arterial hypertension market expansion.

The key to success in developing pulmonary arterial hypertension therapies has been the immense advances in understanding the genetic and molecular mechanisms that drive the pathogenesis of the disease. With the growing knowledge, the treatment strategies will continue to evolve and diversify from the current paradigm focused on vasoconstriction. Clinical trials are exploring the clinical efficacy of novel delivery devices and their utility in other forms of pulmonary hypertension and combination therapies. This will be the standard for clinical trials in the future. Rising clinical trials for drugs development to treat pulmonary arterial hypertension are expected to introduce new trends to the Middle East & Africa pulmonary arterial hypertension market during the forecast period.

On the contrary, side effects of drugs used for treatment of pulmonary arterial hypertension hurdles the growth of Middle East & Africa pulmonary arterial hypertension market.

Based on drugs, the Middle East & Africa pulmonary arterial hypertension market is segmented into endothelin receptor antagonists (eras), prostacyclin and prostacyclin analogs, sGC stimulators, and pde-5 dipsticks. The prostacyclin and prostacyclin analogs segment held 37.7% share of Middle East & Africa pulmonary arterial hypertension market in 2022, amassing US$  154.93 million. It is projected to garner US$ 211.57 million by 2028 to expand at 5.3% CAGR during 2022–2028.

Based on type, the Middle East & Africa pulmonary arterial hypertension market is bifurcated into branded and generics. The branded segment held 63.9% share of Middle East & Africa pulmonary arterial hypertension market in 2022, amassing US$  262.38 million. It is projected to garner US$ 347.17 million by 2028 to expand at 4.8% CAGR during 2022–2028.

Based on route of administration, the Middle East & Africa pulmonary arterial hypertension market is segmented into oral, intravenous/ subcutaneous, and inhalational. The oral segment held 41.3% share of Middle East & Africa pulmonary arterial hypertension market in 2022, amassing US$  169.90 million. It is projected to garner US$ 229.82 million by 2028 to expand at 5.2% CAGR during 2022–2028.

Based on distribution channel, the Middle East & Africa pulmonary arterial hypertension market is segmented into hospital pharmacies and clinics, online pharmacies, and retail pharmacies. The hospital pharmacies and clinics segment held 45.7% share of Middle East & Africa pulmonary arterial hypertension market in 2022, amassing US$ 187.66 million. It is projected to garner US$  253.84 million by 2028 to expand at 5.2% CAGR during 2022–2028.

Based on country, the Middle East & Africa pulmonary arterial hypertension market has been categorized into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa.  Our regional analysis states that Saudi Arabia captured 41.3% share of Middle East & Africa pulmonary arterial hypertension market in 2022. It was assessed at US$ 169.51 million in 2022 and is likely to hit US$ 223.14 million by 2028, exhibiting a CAGR of 4.7% during the forecast period.

Key players profiles in  the Middle East & Africa pulmonary arterial hypertension market report are Bayer AG; Gilead Sciences Inc; GSK Plc; Johnson & Johnson; Lupin Ltd; Novartis AG; Pfizer Inc; and Teva Pharmaceutical Industries Ltd, among others.

Contact Us
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email id: sam@businessmarketinsights.com